Slides
Page 1
June 4, 2025 Q1 FY27 Earnings Call October 29, 2026
Page 2
Data Vis Historical financial and operating data in this presentation reflect the consolidated results of ResMed Inc. ("Resmed"), its subsidiaries, and its legal entities for the periods indicated. This presentation includes financial information prepared in accordance with accounting principles generally accepted in the United States, or GAAP, as well as other financial measures referred to as non-GAAP. The non-GAAP financial measures in this presentation, which include non-GAAP Gross Profit, non-GAAP Gross Margin, non-GAAP Income from Operations, non-GAAP Net Income, and non-GAAP Diluted Earnings per Share, should be considered in addition to, but not as substitutes for, the information prepared in accordance with GAAP. For reconciliations of the non-GAAP financial measures to the most comparable GAAP measures, please refer to the earnings release associated with the relevant reporting period, which can be found on the investor relations section of our corporate website ( investor.Resmed.com). In addition to historical information, this presentation contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on Resmed’s current expectations of future revenue or earnings, new product development, ne w product launches, new markets for its products, integration of acquisitions, the execution of strategic initiatives, leveraging of strategic investments, litigatio n, and outlook. The words “believe,” “expect,” “intend,” “anticipate,” “will continue,” “will,” “estimate,” “plan,” “future” and other similar expressions, and negative statements of such expressions, generally identify forward-looking statements, including, in particular, statements regarding expectations of future revenue or earnings, expenses, new product development, new product launches, new markets for our products, the integration of acquisitions, the execution of strategic initiatives, our , domestic and international regul atory developments, litigation, outlook, and the expected impact of macroeconomic conditions on our business. We have not included a reconciliation for forward-looking non-GAAP financial measures where we are unable to provide a meaningful or accurate calculation or estimation of reconciling items, and the information is not available without unreasonable effort. This is due to the inherent difficulty o f forecasting the occurrence and the financial impact of various items that have not yet occurred, are out of our control, or cannot be reasonably predicted. For the same reasons, we are unable to address the probable significance of the unavailable information. Forward-looking non-GAAP financial measures provided without the most directly comparable GAAP financial measures may vary materially from the corresponding GAAP financial measures. Resmed’s expectations, beliefs, and forecasts are expressed in good faith and are believed to have a reasonable basis, but ac tual results could differ materially from those stated or implied by these forward-looking statements due to risks, uncertainties, and other factors. Resmed assumes no obligation to u pdate the forward-looking information in this presentation, whether as a result of new information, future events, or otherwise. For further discussion of the various factors that could impact actual events or results, please review the “Risk Factors” identified in Resmed’s quarterly and annual reports filed with the SEC. All forward-looking statements included in this presentation should be considered in the context of these risks. Investors and prospective investors are cautioned not to unduly rely on our forward -looking statements. Presentation of financial information & forward-looking statements 2© 2026 Resmed.
Page 3
Data Vis Q1 FY27 Results © 2026 Resmed. 3 Note: Data as of September 30, 2026. Resmed’s fiscal year end is June 30th. Note: See reconciliation to GAAP in Appendix. Note: CC = constant currency. HL = headline. YoY = year-over-year. 1 Includes only 2 months of MatrixCare revenue in both periods and Nidra revenue is excluded. 2 Includes share buybacks and dividends paid. $1.4B Total Revenue 6% HL / 7% Core1 CC YoY growth 62.5% Non-GAAP Gross Margin +50 basis points YoY $2.91 Non-GAAP EPS 14% YoY growth >$1B Capital returned to shareholders2 Continued commitment to build the world’s leading digital health ecosystem
Page 4
Data Vis © 2026 Resmed. 4 Innovation and Operational Excellence Active Portfolio Management Invest in Business and Return Capital to Shareholders Key areas of focus that will continue contributing to Resmed’s growth and transformation 1 2 3 Resmed key areas of focus
Page 5
Data Vis Expanding Device & Fabric Mask Platforms AirTouchTM F40 US launch; 3rd fabric mask; ComfiSoft cushion adapts through the night. 91% rated it comfortable at initial fitting1 AirTouchTM N30i Demonstrated a +6% increase in 90-day compliance over AirFit N30i AirCurve 11 ST / ST-A US bilevel launch for complex sleep apnea & overlap syndrome (OSA + COPD) built on our market- leading Air11 platform Personalized AI-Powered Compliance Smart Comfort (FDA-cleared) Used Resmed’s sleep data to adjust comfort settings 4.3% increase in 30- day compliance vs. default settings TIME Best Inventions 2026 – Special Mention Q1 Innovation updates 5© 2026 Resmed. Note: Data as of September 30, 2026. 1 Resmed external study. 2 Offered in select geographies. I. Innovation & Operational Excellence II. Active Portfolio Management III. Business Investment & Return of Capital Driving Resupply Through Refreshed Patient Experience myAirTM Personalized: new myAir Score, Nightly Timeline, Therapy Control & Equipment Care2 resupply reminders 2.1M+ Dawn GenAI coach inquiries (up 40%)
Page 6
Data Vis Operational improvements and developments 6© 2026 Resmed. I. Innovation & Operational Excellence II. Active Portfolio Management III. Business Investment & Return of Capital 1st Made in America PAP: AirSense 11 (Atlanta) Indiana new distribution center for faster delivery in the US We continue to invest in expanding our capabilities to serve our patients across 140+ countries Ahead of Q1 FY27 expectations; benefited from phasing of supply chain expansion investments Double-digit bps GM improvement every year through 2030 Multi-year robust initiative pipeline AS11 Line at Atlanta Site External Indy site view Gross Margin US Productivity Flexibility Global Manufacturing Footprint Production lines Automated motor assembly line
Page 7
Data Vis Enhancing sleep health awareness and education while improving access to care • Identify: Signs of nighttime breathing disturbances are surfaced in the ŌURA app • Assess: Members access Resmed sleep education and complete the Resmed Sleep Assessment • Connect: Members explore care options through “Find a Clinic” or “Virtual Care” © 2026 Resmed. 7 + + Connecting sleep insights and expanding access to sleep health resources Expanding access to sleep health through key partnerships • Brings together Eight Sleep and Resmed sleep insights in one experience • Gain broader visibility into sleep health and sleep trends over time • Access sleep health education, resources, and assessment tools to learn more about sleep health and available support options Resmed + ŌURA Early KPIs: ~28K Resmed.com visits ~72% of assessment takers undiagnosed Pathway explained: I. Innovation & Operational Excellence II. Active Portfolio Management III. Business Investment & Return of Capital Pathway explained: Note: Data as of September 30, 2026.
Page 8
Data Vis Source: IQVIA LRX data and Diagnostic claims, July 2021 – June 2026. 1 Total patients with an OSA diagnosis claim from July 2021 – June 2026; those who were diagnosed with OSA prior to July 2021 arenot included in this analysis. 2 GLP-1 initiation is defined by presence of GLP-1 claim at any point from July 2021 – June 2026 (n=3,307k patients); initiationdoes not demonstrate GLP-1 treatment adherence, so patients may not be actively taking GLP-1s today. 3 Values show absolute percentage difference in presence of any PAP-related claim from July 2021 – June 2026 comparing OSA patients who used GLP-1s versus OSA patients with no GLP-1 use. 4 Values show absolute percentage difference in presence of any PAP-related claim at each timepoint post PAP setup from July 2021– June 2026 comparing OSA patients who used GLP-1s versus OSA patients with no GLP-1 use. 5 Patient counts have been updated to reflect additional claims data from IQVIA. 6 Majority of patients in the analysis population were prescribed newer GLP-1 drugs: semaglutide or tirzepatide. Large real-world data analysis: n = 3,307,000 patients5 with GLP-1 initiation, sleep apnea diagnosis, and Rx for PAP therapy6 Note: CPAP + GLP-1 and CPAP-only cohorts are measured on the same basis: patients who stop CPAP remain in the base population for both. Patients with an OSA diagnosis and prescribed a GLP-1 drug are more likely to initiate PAP therapy and have higher PAP resupply rates GLP-1 initiated1,2 vs. non-GLP-1 initiated OSA patients1 PAP resupply rates4 1-year post-setup +350 bps +1170 bps GLP-1Non-GLP-1 Likely to initiate PAP therapy3 PAP resupply rates4 3-year post-setup +730 bps Real-world data analysis now shows >3.3M patients on GLP-1s both initiate CPAP more and stay on therapy 8© 2026 Resmed. GLP-1Non-GLP-1 GLP-1Non-GLP-1 I. Innovation & Operational Excellence II. Active Portfolio Management III. Business Investment & Return of Capital
Page 9
Data Vis 9© 2026 Resmed. I. Innovation & Operational Excellence II. Active Portfolio Management III. Business Investment & Return of Capital Normalizing CPAP through 1) cultural relevance, 2) community-led social growth, and 3) expanding into category conversation Q1 Marketing is expanding awareness and improving patient lives Our partnership with Tyler Reddick and 23XI Racing brings the sleep health conversation to a new audience Series of conversations positioning Resmed as a trusted, culturally relevant voice at the intersection of sleep, performance, and health CPAP Baddies “In Bed With” Series Athlete Partnerships Olympic athlete, filmmaker and author Alexi Pappas and sleep physician Cheri D. Mah, MD, MS discussing sleep-driven, peak performance: “The ones benefitting most (from Tyler being on therapy) are me and my kids… his presence is more productive, more engaging, Tyler is (now) more of a team player, and a dad” – Alexa, Tyler’s wife, on Tyler’s CPAP journey
Page 10
Data Vis ✓ ~108,000 CME courses completed ✓By >63,000 unique clinicians ✓With ~75% Saying they intend to change their clinical practices with regards to OSA Clinicians are highly engaged with Resmed education programs focused on sleep 10 Up ~13K Up ~8K Note: Data as of September 30, 2026. Note: Data compares Q1 FY27 values vs. Q4 FY26 values. © 2026 Resmed. I. Innovation & Operational Excellence II. Active Portfolio Management III. Business Investment & Return of Capital
Page 11
Data Vis Prioritizing higher-growth, higher-return opportunities 11© 2026 Resmed. I. Innovation & Operational Excellence II. Active Portfolio Management III. Business Investment & Return of Capital Note: Data as of September 30, 2026. 1 Includes MatrixCare, HEALTHCAREfirst, Citus, and select home health and hospice solutions. Nidra is a novel, non-invasive therapy for restless legs syndrome (RLS); acquired via Noctrix Health ✓ Commercial footprint expanding rapidly ✓ Good early integration progress ✓ Priority: expand commercial coverage and patient access ✓ Accelerates growth and profitability of core RCS ✓ FY27 RCS outlook reiterated: high single-digit revenue growth, with operating leverage ✓ Improved mix and sharper execution focus Closed September 1, 2026 Closed June 1, 2026 Nidra Acquisition MatrixCare Business1 Divestiture Strategic Rationale Strategic Rationale
Page 12
Data Vis + Tremendous market opportunity + Leading market position + Very strong balance sheet + Proven execution track record, anchored by our 2030 strategy Why we are confident:5-Year Global Outlook High single-digit % Revenue Growth Earnings growth higher than revenue growth Record shareholder returns; confident in our 5-year outlook 12© 2026 Resmed. ✓ Record >$1B1 returned to shareholders in Q1 FY27 ✓ ~$936M in buybacks, incl. ASR funded by MatrixCare business2 divestiture proceeds ✓ High ROI conviction in investing in Resmed Shareholder Returns I. Innovation & Operational Excellence II. Active Portfolio Management III. Business Investment & Return of Capital Note: Data as of September 30, 2026. 1 Includes share buybacks and dividends paid. 2 Includes MatrixCare, HEALTHCAREfirst, Citus, and select home health and hospice solutions.
Page 13
Financial Results and FY 2027 Guidance Q1
Page 14
Data Vis Q1 FY27 Global revenue results 14 Residential Care Software Total Revenue $1.3 $1.4 Q1 FY26 Q1 FY27 Americas Sleep Devices Revenue RoW Sleep Devices Revenue Americas Masks & Other Revenue RoW Masks & Other Revenue Americas Life Support Devices Revenue RoW Life Support Devices Revenue $166 $155 Q1 FY26 Q1 FY27 $405 $436 Q1 FY26 Q1 FY27 $361 $397 Q1 FY26 Q1 FY27 $9 <$1 Q1 FY26 Q1 FY27 $250 $280 Q1 FY26 Q1 FY27 $128 $143 Q1 FY26 Q1 FY27 $17 $3 Q1 FY26 Q1 FY27 +8% ⇧ (27%) ⇩ +9% ⇧ +9% ⇧ +12% ⇧ +5% ⇧+6% ⇧+6% ⇧ +7% ⇧ (94%) ⇩ (79%) ⇩ +6% ⇧ +10% ⇧ +11% ⇧+13% ⇧+5% / +8%1 ⇧ ($ in billions) © 2026 Resmed. Note: Data as of September 30, 2026. Resmed’s fiscal year end is June 30th. All $ in millions, unless noted otherwise. Note: All growth rates are year-over-year on a core constant currency (CCC) basis. RoW = Rest of World. Note: Year-over-year core constant currency metrics by segment for FY26 are provided in the Appendix. 1 The remaining Residential Care Software business – Brightree and MEDIFOX Dan - increased by 8%.
Page 15
Data Vis 62.0% 62.5% Q1 FY26 Q1 FY27 $2.55 $2.91 Q1 FY26 Q1 FY27 36.1% 35.8% Q1 FY26 Q1 FY27 $414 $374 Q1 FY26 Q1 FY27 15 Q1 FY27 Rest of P&L © 2026 Resmed. Non-GAAP Operating Margin Non-GAAP Gross Margin Non-GAAP Earnings Per Share Free Cash Flow1 ($ in actuals) ($ in millions) 50 bps ⇧ +14% ⇧ 30 bps ⇩ (10%) ⇩ Note: Data as of September 30, 2026. Resmed’s fiscal year end is June 30th. Note: All growth rates are year-over-year on a headline basis. Note: See reconciliation to GAAP in Appendix. 1 Free cash flow = Cash flow from operations – Capital expenditures.
Page 16
Data Vis Reiterating FY27 Revenue guidance 16© 2026 Resmed. Note: Data as of September 30, 2026. Resmed’s fiscal year end is June 30th. Note: CC = constant currency. HL = headline. RoW = Rest of World. YoY = year-over-year. 5% - 7% YoY Core CC Revenue Growth Includes ~130 bps (or) ~$75M headwind from Astral For FY27 & FY26: • Only 2 months of MatrixCare revenue included • Nidra revenue excluded $5.75B - $5.85B HL Total Revenue For FY27: • Only 2 months of MatrixCare revenue included • Nidra revenue included • Now assumes FX headwind of ~60 bps (vs. ~50) Key assumptions underpinning guidance: Net price realization as we continue to roll out pricing increases globally 1 Successful execution of our marketing campaigns 2 2H FY27 pressure in our RoW sleep devices as France fleet renewal concludes 3 External environment, including continued inflationary impact 4
Page 17
Data Vis Reiterating FY27 Fully diluted non-GAAP EPS guidance 17© 2026 Resmed. $11.17 ($0.20) ($0.30) FY26 EPS (-) Noctrix (-) MatrixCare (+) Core contribution FY27 EPS $12.00 - $12.25112% - 14% Growth Note: Data as of September 30, 2026. Resmed’s fiscal year end is June 30th. Note: All forward looking non-GAAP fully diluted EPS figures are approximates. 1 Includes a total of ~$1.5 billion in share repurchases, including a $450 million ASR. $1.33 - $1.58
Page 18
Data Vis Reiterating FY27 P&L margin outlook 18© 2026 Resmed. Non-GAAP Gross Margin Low-double-digit basis point expansion for FY27 vs. FY26; with variability quarter-to-quarter Non-GAAP Operating Margin Slight increase for FY27 vs. FY26; productivity and efficiency-driven Note: Data as of September 30, 2026. Resmed’s fiscal year end is June 30th.
Page 19
Data Vis Strategic Growth Priorities Capital Returns to Shareholders Reiterating FY27 capital expenditures of $160 - 180 million, supporting automation expansion and manufacturing footprint to address growing global demandCapEx Priorities Tuck-in size acquisitions: up to ~$500 million purchase pricePursue M&A FY27 quarterly dividend $0.66 per share; progressive dividend policySupport Dividends • FY27 share repurchases ~$1.5 billion, including $450M ASR • Significant progress made in Q1: $936 million repurchased through an ASR and open market repurchases Share Repurchases Disciplined capital allocation strategy supports both business growth and return of capital to shareholders 19© 2026 Resmed. Note: Data as of September 30, 2026. Resmed’s fiscal year end is June 30th.
Page 20
Data Vis Mid-single-digit QoQ increase1 Q2 FY27 Preliminary trends 20© 2026 Resmed. Note: Data as of September 30, 2026. Resmed’s fiscal year end is June 30th. Note: QoQ = quarter-over-quarter. 1 Includes only 2 months of MatrixCare revenue in both periods and Nidra revenue is excluded. Total Revenue Growth (%) Slightly down QoQ Non-GAAP Gross Margin (%) Roughly flat QoQ R&D Expenses ($) Up low-single-digit QoQ SG&A Expenses (% Change) Down ~$10 million QoQ Net Other Income ($)
Page 21
Data Vis Growth • Investing in the highest-ROI R&D and marketing initiatives • Optimizing the patient experience • Converting new patients entering the funnel • Expanding the sleep opportunity Shareholder Returns • Returned >$1B to shareholders this quarter • Enhanced transparency • Commitment to dividend and opportunistic buybacks • Evaluating capital structure Transformation • Driving efficiencies • Active portfolio management • Selectively evaluating M&A • Leveraging AI and technology to transform and improve productivity 21© 2026 Resmed. Q1 FY27 Progress in key business priorities
Page 22
Contact Investor Relations Phone: +1 (858) 221-3304 Email: InvestorRelations@Resmed.com Website: Investor.Resmed.com
Page 23
APPENDIX
Page 24
Data Vis Q1 – Q4 FY26 Global core constant currency revenue growth 24© 2026 Resmed. Note: Data as of September 30, 2026. Resmed’s fiscal year end is June 30th. All $ in millions, unless noted otherwise. Note: All growth rates are year-over-year on a core constant currency (CCC) basis. RoW = Rest of World. Revenue $ Core CC growth % Q1 FY26 Q2 FY26 Q3 FY26 Q4 FY26 Q1 FY26 Q2 FY26 Q3 FY26 Q4 FY26 Americas Sleep Devices $405 $438 $436 $452 9% 10% 7% 8% Life Support Devices $9 $10 $11 $7 (27%) (41%) (29%) (45%) RoW Sleep Devices $250 $266 $276 $281 6% 6% 9% 13% Life Support Devices $17 $12 $12 $10 9% (15%) (30%) (38%)
Page 25
Data Vis More than 29 billion nights of respiratory medical data (up ~1B) 39+ million patients in AirView 36+ million 100% cloud connectable devices worldwide 25 4.9+ million diagnostic tests processed in the cloud v Up ~0.1M Up ~1M 13.2+ million patients have signed up for myAir v Up ~0.7M Up ~1M © 2026 Resmed. Note: Data as of September 30, 2026. Note: Data compares Q1 FY27 values vs. Q4 FY26 values. Note: All metrics are cumulative since their respective launch, with the exception of the API calls per second from integrators. Unmatched scale in connected respiratory & digital health 460+ API calls per second from integrators v
Page 26
Data Vis 400M RLS 480M COPD 1B+ People Sleep Apnea Underpenetrated OSA Market1 Sources (Lives in TAM): Sleep apnea – 936M, Benjafield et al Lancet Respir Med 2019 Insomnia – Sleep Medicine Reviews, Benjafield et al., August 2025 COPD – 480M, Boers et al JAMA Network Open 2023 Sleep Stats from Resmed 2026 sleep survey https://sleepsurvey.resmed.com/ 1. Resmed 2025 10-K 2. Resmed and Lancet Respiratory Medicine August 2025 M A R K ET F O R D EV I C ES M A R K ET F O R M A S K S Growing in the mid-single digits globally Growing in the high-single digits globally OSA patients diagnosed or treated <20% U.S. <10% Rest of World 2.7 B + People 850M Insomnia People who need health tech at home U.S. OSA Prevalence to Increase2 DRIVERS Aging | Higher average BMIs | 65% relative increase in prevalence in women GLP-1s impact limited (4%) ~77M adults by 2050 ~35% From 2020 Large, underpenetrated total addressable market = long runway for growth 26© 2026 Resmed. COMISA Overlap syndrome
Page 27
Data Vis Consumers are more focused on their health than ever before Wearables spotlight sleep apnea and sleep quality in general Consumers demand an elevated experience for healthcare products AI and digital health are changing how healthcare is delivered Massive pressure on healthcare systems; payers / providers are laser-focused on preventative care1 Widespread adoption of GLP-1 medications increases awareness of sleep apnea 1 Study published in SLEEP in 2026 involving 370k+ patients (including those with co-existing chronic diseases COPD, type 2 diabetes, depression, heart failure, and atrial fibrillation) and the medXcloud academic-industry collaborative, found (a) a consistent, dose-dependent reduction in hospitalizations and ER visits across all 5 comorbidity groups; (b) benefits emerging at just 2 to <4 hours of average nightly PAP use; (c ) each additional hour of PAP use linked to a 4.1-6.2% reduction in healthcare utilization over 12-24 months (p < 0.0001). Key megatrends are driving patients and providers to Resmed’s ecosystem 27© 2026 Resmed.
Page 28
Data Vis Reconciliation of non-GAAP financial measures In addition to financial information prepared in accordance with GAAP, we use certain non-GAAP financial measures, such as non-GAAP core constant currency basis, non-GAAP gross profit, non-GAAP gross margin, non-GAAP income from operations, non-GAAP operating margin, non- GAAP net income, and non-GAAP diluted earnings per share, in evaluating the performance of our business. We believe that these non-GAAP financial measures, when reviewed in conjunction with GAAP financial measures, can provide investors better insight when eval uating our performance from core operations and can provide more consistent financial reporting across periods. For these reasons, we use non-GAAP information internally in planning, forecasting, and evaluating the results of operations in the current period and in compar ing it to past periods. These non-GAAP financial measures should be considered in addition to, and not superior to or as a substitute for, GAAP financia l measures. We strongly encourage investors and shareholders to review our financial statements and publicly-filed reports in their entirety and not to rely on any single financial measure. Like all non-GAAP measures, non-GAAP earnings are subject to inherent limitations because they do not include all the expenses that must be included under GAAP. Non-GAAP financial measures as presented herein may not be comparable to similarly titled measures used by other companies. The non-GAAP financial measures included in this release and the accompanying tables (including within the tables that provide our detailed reconciliations to the corresponding GAAP financial measures) are adjusted for the impact of acquisitions and divestitures, a mortization of acquired intangibles, restructuring and business transformation expenses, acquisition and divestment-related expenses, gains on divestment of subsidiaries, and associated tax effects, in addition to the tax effect of interest and penalties on tax refunds. We have not included a reconciliation of forward-looking non-GAAP financial measures where we are unable to provide a meaningful or accurate calculation or estimation of reconciling items, and the information is not available without unreasonable effort. This is due to the inherent difficulty of forecasting the occurrence and the financial impact of various items that have not yet occurred, are out of our control, or cannot be reasonably predicted. For the same reasons, we are unable to address the probable significance of the unavailable information. Forward-looking non-GAAP financial measures provided without the most directly comparable GAAP financial measures may vary materially from the corresponding GAAP financial measures. Non-GAAP measures are reconciled to their most directly comparable GAAP financial measures below (in millions, except percentages): 28© 2026 Resmed.
Page 29
Data Vis Reconciliation of non-GAAP financial measures (cont’d) 29© 2026 Resmed. (Unaudited; $ in millions, except for per share amounts) Note regarding non-GAAP reconciliations (A) In order to provide a framework for assessing how our underlying businesses performed excluding the impact of the Noctrix acquisition and the divestiture of the MatrixCare business and the effect of foreign currency fluctuations, when applicable, we provide certain financial information on a “core constant currency basis,” which is in addition to the actual financial information presented. In order to calculate our constant currency information, we translate the current period financial information using the foreign currency exchange rates that were in effect during the previous comparable period. However, constant currency measures should not be considered in isolation or as an alternative to U.S. dollar measures that reflect current period exchange rates, or to other financial measures calculated and presented in accordance with U.S. GAAP.
Page 30
Data Vis Reconciliation of non-GAAP financial measures (cont’d) (Unaudited; $ in millions, except for per share amounts) 30© 2026 Resmed. Note regarding non-GAAP reconciliations (A) Totals may not add due to rounding.
Page 31
Data Vis Reconciliation of non-GAAP financial measures (cont’d) (Unaudited; $ in millions, except for per share amounts) 31© 2026 Resmed. Note regarding non-GAAP reconciliations (A) Totals may not add due to rounding.
Page 32
Data Vis Reclassification of Prior-period Amounts During the first quarter of fiscal year 2027, we revised the presentation of restructuring expenses and amortization of acquired intangibles in our condensed consolidated statements of operations. Restructuring expenses, which were previously presented as a separate line item within operating expenses, are now classified within cost of sales, research and development expenses, and selling, general and administrative expenses based on the function of the associated costs. In connection with this change, we renamed "restructuring expenses" as "restructuring and business transformation expenses" to reflect the broader nature of the costs included within this category. Amortization of acquired intangibles relating to cost of sales is no longer presented as a separate line item within cost of sales. Amortization of acquired intangibles relating to operating expenses are now classified within selling, general and administrative expenses. Prior-period amounts have been reclassified to conform to the current-period presentation. The reclassifications had no effect on previously reported income from operations, income before income taxes, net income, earnings per share or cash flows. 32© 2026 Resmed.
Page 33
Data Vis Reclassification of Prior-period Amounts (cont’d) (Unaudited; $ in thousands) 33© 2026 Resmed. The following table reconciles previously reported quarterly 2026 amounts to the revised presentation (in thousands):
Page 34
Data Vis Reclassification of Prior-period Amounts (cont’d) (Unaudited; $ in thousands) 34© 2026 Resmed. The following table reconciles previously reported quarterly 2026 amounts to the revised presentation (in thousands):
Page 35
Data Vis Reclassification of Prior-period Amounts (cont’d) (Unaudited; $ in thousands) 35© 2026 Resmed. The following table reconciles previously reported quarterly 2026 amounts to the revised presentation (in thousands):
Page 36
Data Vis Reclassification of Prior-period Amounts (cont’d) (Unaudited; $ in thousands) 36© 2026 Resmed. The following table reconciles previously reported quarterly 2026 amounts to the revised presentation (in thousands):